Comments
About 135 million more doses of Johnson & Johnson's Covid-19 vaccine from a troubled Baltimore factory will have to be destroyed due to quality problems, Congressional panel leaders said Thursday.
The announcement follows a report in May that detailed how more than 400 million vaccine doses made at an Emergent BioSolutions plant had to be trashed. The doses more recently slated for destruction were made between August 2021 and February, the House members said.
Johnson & Johnson said in a statement Thursday that no doses produced at the site since the factory restarted have reached the market, and it was ending its agreement with Emergent.
Related Stories
FDA restricts J&J's Covid-19 vaccine due to blood clot risk
The FDA authorised J&J's shot in February last year for adults 18 and upThe doses had been set aside after they were made. The panel said J&J told it that a batch of the shots failed inspection, which rendered all of them unusable.
The factory's problems have hurt vaccinations in areas of the world where vaccines are still in short supply, said US Rep. Jim Clyburn, a South Carolina Democrat and Covid-19 subcommittee chairman.
Emergent said it has been “open and forthcoming” about the factory's challenges. It noted that J&J took control of the plant after problems first emerged and that J&J was in charge until manufacturing stopped there earlier this year.
The problem-plagued Baltimore factory was initially shut down by the Food and Drug Administration in early 2021 due to contamination. The government then allowed production to resume in August 2021.
J&J's vaccine was one of three initially authorised by US regulators more than a year ago to protect against Covid-19. But the government has since strictly limited who can receive the shot due to a small risk of rare but serious blood clots.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.